Please assess the completion status of the following clinical trial:

Trial Title: Recombinant Human Prolactin for Lactation Induction

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: DOUBLE
- Phase: PHASE2
- Number of Arms: 3.0

Eligibility Criteria:
Inclusion Criteria:~* Healthy women, aged 18-45 years~* Lactation insufficiency postpartum~* Subjects will be women with children in the neonatal Intensive Care Unit (ICU) who are pumping breast milk for their infant's nutritional support and to maintain their milk supply.~* Subjects will have given birth at a gestational age of at least 24 weeks, and will generally be recruited 4-8 weeks postpartum.~Exclusion Criteria:~* Medications known to increase prolactin~* Anatomical breast abnormalities~* Use of medication contraindicated in breastfeeding mothers~* Allergies to mannitol~* Current use of hormonal contraception~* Previous mammoplasty or breast augmentation, unless they have successfully nursed an infant for 3 months in the past without requiring supplemental formula.

- Gender: FEMALE
- Minimum Age: 18 Years
- Maximum Age: 45 Years
- Healthy Volunteers: f

Study Arms:
- 1 (Type: ACTIVE_COMPARATOR): Placebo group normal saline twice per day
- 2 (Type: ACTIVE_COMPARATOR): Recombinant human prolactin 60 mcg/kg every 12 hours
- 3 (Type: ACTIVE_COMPARATOR): Recombinant human prolactin 60 mcg/kg alternating with normal saline placebo every 12 hours

Based on this trial design, predict the completion outcome and termination type (if applicable).